The origins of urothelial carcinoma

Liang Cheng, Darrell Davidson, Gregory T. MacLennan, Sean R. Williamson, Shaobo Zhang, Michael Koch, Rodolfo Montironi, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

It is now widely believed that there are two major pathways for urothelial carcinogenesis. One pathway usually involves mutation of FGF receptor 3 and gives rise to low-grade papillary tumors that frequently recur but seldom invade. By contrast, high-grade urothelial malignancies, including high-grade papillary urothelial carcinoma and urothelial carcinoma in situ (CIS) usually exhibit deletions or mutations of TP53. Urothelial CIS is the most likely precursor of high-grade invasive bladder cancer. It is a 'flat lesion that may be relatively inconspicuous at cystoscopy, or even endoscopically undetectable. The clinical hazards associated with this elusive and biologically dangerous neoplasm have been increasingly well documented since the original studies by Melicow in 1952. Primary or secondary urothelial dysplasia is even more challenging to detect and diagnose than CIS. It is theorized that dysplasia may antedate the onset of CIS, but support for the putative progression of dysplasia to CIS is found in fewer than 20% of cases. Since many benign urothelial changes may resemble CIS at cystoscopy, in biopsies and even with molecular profiling, care must be exercised when making a diagnosis of CIS. For patients whose screening tests are worrisome for the presence of premalignant urothelial disease, newer bladder imaging modalities, including Raman spectral imaging and optical coherence tomography, may enable improved biopsy site selection. In this article, we discuss the above-noted topics, as well as other related issues, such as the possible role of papillary urothelial hyperplasia as a preneoplastic lesion and the roles of cancer stem cells and field cancerization in urothelial carcinogenesis.

Original languageEnglish
Pages (from-to)865-880
Number of pages16
JournalExpert Review of Anticancer Therapy
Volume10
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Carcinoma in Situ
Carcinoma
Cystoscopy
Carcinogenesis
Urinary Bladder Diseases
Biopsy
Fibroblast Growth Factor Receptors
Neoplasms
Neoplastic Stem Cells
Sequence Deletion
Papillary Carcinoma
Optical Coherence Tomography
Urinary Bladder Neoplasms
Hyperplasia
Mutation

Keywords

  • Carcinogenesis
  • Carcinoma in situ
  • Dysplasia
  • Early detection
  • FGFR3
  • Field cancerization
  • Field effect
  • Molecular genetics
  • Precursor lesion
  • TP53 mutation
  • Transitional cell (urothelial) carcinoma
  • Tumorigenesis
  • Urinary bladder
  • Urothelial carcinoma in situ

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Cheng, L., Davidson, D., MacLennan, G. T., Williamson, S. R., Zhang, S., Koch, M., ... Lopez-Beltran, A. (2010). The origins of urothelial carcinoma. Expert Review of Anticancer Therapy, 10(6), 865-880. https://doi.org/10.1586/era.10.73

The origins of urothelial carcinoma. / Cheng, Liang; Davidson, Darrell; MacLennan, Gregory T.; Williamson, Sean R.; Zhang, Shaobo; Koch, Michael; Montironi, Rodolfo; Lopez-Beltran, Antonio.

In: Expert Review of Anticancer Therapy, Vol. 10, No. 6, 06.2010, p. 865-880.

Research output: Contribution to journalArticle

Cheng, L, Davidson, D, MacLennan, GT, Williamson, SR, Zhang, S, Koch, M, Montironi, R & Lopez-Beltran, A 2010, 'The origins of urothelial carcinoma', Expert Review of Anticancer Therapy, vol. 10, no. 6, pp. 865-880. https://doi.org/10.1586/era.10.73
Cheng, Liang ; Davidson, Darrell ; MacLennan, Gregory T. ; Williamson, Sean R. ; Zhang, Shaobo ; Koch, Michael ; Montironi, Rodolfo ; Lopez-Beltran, Antonio. / The origins of urothelial carcinoma. In: Expert Review of Anticancer Therapy. 2010 ; Vol. 10, No. 6. pp. 865-880.
@article{26e56ed4e8f94ed0a273bdd3b172f8ec,
title = "The origins of urothelial carcinoma",
abstract = "It is now widely believed that there are two major pathways for urothelial carcinogenesis. One pathway usually involves mutation of FGF receptor 3 and gives rise to low-grade papillary tumors that frequently recur but seldom invade. By contrast, high-grade urothelial malignancies, including high-grade papillary urothelial carcinoma and urothelial carcinoma in situ (CIS) usually exhibit deletions or mutations of TP53. Urothelial CIS is the most likely precursor of high-grade invasive bladder cancer. It is a 'flat lesion that may be relatively inconspicuous at cystoscopy, or even endoscopically undetectable. The clinical hazards associated with this elusive and biologically dangerous neoplasm have been increasingly well documented since the original studies by Melicow in 1952. Primary or secondary urothelial dysplasia is even more challenging to detect and diagnose than CIS. It is theorized that dysplasia may antedate the onset of CIS, but support for the putative progression of dysplasia to CIS is found in fewer than 20{\%} of cases. Since many benign urothelial changes may resemble CIS at cystoscopy, in biopsies and even with molecular profiling, care must be exercised when making a diagnosis of CIS. For patients whose screening tests are worrisome for the presence of premalignant urothelial disease, newer bladder imaging modalities, including Raman spectral imaging and optical coherence tomography, may enable improved biopsy site selection. In this article, we discuss the above-noted topics, as well as other related issues, such as the possible role of papillary urothelial hyperplasia as a preneoplastic lesion and the roles of cancer stem cells and field cancerization in urothelial carcinogenesis.",
keywords = "Carcinogenesis, Carcinoma in situ, Dysplasia, Early detection, FGFR3, Field cancerization, Field effect, Molecular genetics, Precursor lesion, TP53 mutation, Transitional cell (urothelial) carcinoma, Tumorigenesis, Urinary bladder, Urothelial carcinoma in situ",
author = "Liang Cheng and Darrell Davidson and MacLennan, {Gregory T.} and Williamson, {Sean R.} and Shaobo Zhang and Michael Koch and Rodolfo Montironi and Antonio Lopez-Beltran",
year = "2010",
month = "6",
doi = "10.1586/era.10.73",
language = "English",
volume = "10",
pages = "865--880",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - The origins of urothelial carcinoma

AU - Cheng, Liang

AU - Davidson, Darrell

AU - MacLennan, Gregory T.

AU - Williamson, Sean R.

AU - Zhang, Shaobo

AU - Koch, Michael

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

PY - 2010/6

Y1 - 2010/6

N2 - It is now widely believed that there are two major pathways for urothelial carcinogenesis. One pathway usually involves mutation of FGF receptor 3 and gives rise to low-grade papillary tumors that frequently recur but seldom invade. By contrast, high-grade urothelial malignancies, including high-grade papillary urothelial carcinoma and urothelial carcinoma in situ (CIS) usually exhibit deletions or mutations of TP53. Urothelial CIS is the most likely precursor of high-grade invasive bladder cancer. It is a 'flat lesion that may be relatively inconspicuous at cystoscopy, or even endoscopically undetectable. The clinical hazards associated with this elusive and biologically dangerous neoplasm have been increasingly well documented since the original studies by Melicow in 1952. Primary or secondary urothelial dysplasia is even more challenging to detect and diagnose than CIS. It is theorized that dysplasia may antedate the onset of CIS, but support for the putative progression of dysplasia to CIS is found in fewer than 20% of cases. Since many benign urothelial changes may resemble CIS at cystoscopy, in biopsies and even with molecular profiling, care must be exercised when making a diagnosis of CIS. For patients whose screening tests are worrisome for the presence of premalignant urothelial disease, newer bladder imaging modalities, including Raman spectral imaging and optical coherence tomography, may enable improved biopsy site selection. In this article, we discuss the above-noted topics, as well as other related issues, such as the possible role of papillary urothelial hyperplasia as a preneoplastic lesion and the roles of cancer stem cells and field cancerization in urothelial carcinogenesis.

AB - It is now widely believed that there are two major pathways for urothelial carcinogenesis. One pathway usually involves mutation of FGF receptor 3 and gives rise to low-grade papillary tumors that frequently recur but seldom invade. By contrast, high-grade urothelial malignancies, including high-grade papillary urothelial carcinoma and urothelial carcinoma in situ (CIS) usually exhibit deletions or mutations of TP53. Urothelial CIS is the most likely precursor of high-grade invasive bladder cancer. It is a 'flat lesion that may be relatively inconspicuous at cystoscopy, or even endoscopically undetectable. The clinical hazards associated with this elusive and biologically dangerous neoplasm have been increasingly well documented since the original studies by Melicow in 1952. Primary or secondary urothelial dysplasia is even more challenging to detect and diagnose than CIS. It is theorized that dysplasia may antedate the onset of CIS, but support for the putative progression of dysplasia to CIS is found in fewer than 20% of cases. Since many benign urothelial changes may resemble CIS at cystoscopy, in biopsies and even with molecular profiling, care must be exercised when making a diagnosis of CIS. For patients whose screening tests are worrisome for the presence of premalignant urothelial disease, newer bladder imaging modalities, including Raman spectral imaging and optical coherence tomography, may enable improved biopsy site selection. In this article, we discuss the above-noted topics, as well as other related issues, such as the possible role of papillary urothelial hyperplasia as a preneoplastic lesion and the roles of cancer stem cells and field cancerization in urothelial carcinogenesis.

KW - Carcinogenesis

KW - Carcinoma in situ

KW - Dysplasia

KW - Early detection

KW - FGFR3

KW - Field cancerization

KW - Field effect

KW - Molecular genetics

KW - Precursor lesion

KW - TP53 mutation

KW - Transitional cell (urothelial) carcinoma

KW - Tumorigenesis

KW - Urinary bladder

KW - Urothelial carcinoma in situ

UR - http://www.scopus.com/inward/record.url?scp=77953774777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953774777&partnerID=8YFLogxK

U2 - 10.1586/era.10.73

DO - 10.1586/era.10.73

M3 - Article

C2 - 20553211

AN - SCOPUS:77953774777

VL - 10

SP - 865

EP - 880

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -